SPAC Sponsor Research: A Diligence Field Guide

A practical guide to SPAC sponsor diligence: regulatory pressure, litigation risks, what good research looks like, and the checklist to use before committing capital.

Published
19 August 2026
Author
Francisca Florin

SPAC sponsor research is the process of evaluating the people, incentives, and track records behind special purpose acquisition companies before you commit capital to a deal. It matters more now than it did three years ago, and it matters for a specific reason: the securities and exchange commission has tightened rules on SPAC disclosures since 2024, and courts have shown they'll hold SPAC sponsors personally accountable for sloppy diligence.

A SPAC is a shell company with no operations. It exists to raise capital through an initial public offering, find a private company to acquire, and bring that target public through a de-SPAC transaction. At peak, SPACs raised approximately $113 billion across 366 IPOs in 2021. By 2023, that number collapsed to roughly $3.85 billion across just 31 IPOs. The SPAC market in 2025 and 2026 has partially recovered, but with tighter regulatory scrutiny and far more litigation risk baked into every deal.

Sponsors, PIPE investors, and PE/VC funds now treat sponsor diligence as seriously as target company diligence. That's because Securities Act and Exchange Act exposure doesn't stop at the target's financials. It extends to the sponsor's conduct, projections, conflicts of interest, and the quality of the diligence process itself. If you're deploying capital into a SPAC deal, your SPAC research on the sponsor is your first line of defense — and it sits alongside the commercial diligence you'd run on any other target.

FieldSignal fits into this process as an on-demand expert network. We connect sponsors, co-investors, and boards with former employees, customers, suppliers, and sector specialists for focused interview programs. You get a reality check on both the target and the sponsor's claims, without six-figure annual retainers. Pay-per-use, no minimums, no markups on expert honoraria.

SPAC basics: where sponsor research fits in the lifecycle

Here's the lifecycle in five steps, stripped to what matters for diligence:

  1. Sponsor formation and fundraise. A sponsor team, typically seasoned industry executives and financial experts, forms an acquisition corp. They provide initial risk capital for underwriting and compliance fees. SPAC sponsors typically receive a 20% stake for minimal investment, known as the promote.

  2. SPAC IPO stage. The shell company files a Form S-1 and lists SPAC shares on a stock exchange. SPAC IPOs typically have lower disclosure requirements than a traditional IPO because there's no operating business to describe. SPAC securities constituting the initial public offering usually include units (common stock plus warrants). The financial industry regulatory authority and exchange rules govern listing standards.

  3. Target search. The sponsor has 18 to 24 months to find and close a deal. When a SPAC identifies a target, real diligence begins. Sponsors conduct due diligence to evaluate a private company's viability as a public entity.

  4. De-SPAC transaction. A de-SPAC transaction involves a proxy statement or Form S-4 filing with detailed disclosures about the target, financial projections, and merger consideration. Investors can redeem shares if they disapprove a merger. Sponsors organize private investment in public equity deals to raise additional capital and validate the valuation. PIPE investment is used to ensure deal completion and validate valuation.

  5. Post-closing. The acquired company becomes a publicly traded SPAC successor. Sponsors often secure board seats to help scale the business post-merger.

Unlike a traditional IPO process, where an existing operating company issues shares publicly and goes through months of bank-led roadshows, the risk profile in SPAC transactions concentrates in the de-SPAC disclosures and projections. That's where sponsor conduct and research quality get scrutinized.

Who cares about sponsor research:

Regulatory pressure: why sponsor diligence got real after 2021-2024

The SPAC boom from 2019 through the first half of 2021 produced over $100 billion in annual SPAC IPO volume and triggered attention from both the SEC and the plaintiff bar. Shareholders filed 30 federal class action lawsuits involving SPACs from 2019 to 2021. Over 60 shareholder lawsuits involving SPACs were filed in state courts during the same period. Regulators took notice.

Here are the concrete regulatory milestones that changed the game:

Regulators now examine sponsor incentives, promote economics, and diligence process quality when assessing alleged misstatements under the securities act and the securities exchange act. Mitigating SPAC litigation risks requires documented, substantive research, not checkbox compliance.

Core litigation risks tied to SPAC sponsors

Litigation against SPAC sponsors clusters around three themes:

Disclosure accuracy. Plaintiffs allege that financial projections in proxy statements or S-4 filings lacked a factual basis. Revenue forecasts, subscriber counts, technology claims, and past financial performance metrics turn out to be overstated or fabricated. In the Akazoo case, the company went public via SPAC in 2019, and the SEC later found that claims of paying subscribers and revenue were entirely false. The SEC settled for approximately $38.8 million.

Conflicts of interest. SPAC sponsors typically receive 20% of the equity for minimal investment. That economic interest creates pressure to close any deal rather than the right deal. Warrant packages, side letters, and sponsor compensation structures can misalign sponsors with public shareholders. Courts have found these conflicts severe enough to trigger heightened scrutiny.

Process failures. Due diligence failures can lead to shareholder litigation in SPACs. In the MultiPlan case, Delaware Chancery held that the sponsor and board may have breached the defendant's fiduciary duties by failing to disclose that the target's largest customer was developing a competing technology. The court applied the entire fairness standard because of the sponsor's acute conflicts.

Performance data makes this concrete. SPACs launched in 2019 had mean returns of negative 12.3%. SPACs had returns of negative 74% in 2022 and negative 67% in 2023. Investors may face dilution from subsequent fundraising efforts. These numbers fuel litigation.

The most recurring allegations against SPAC sponsors:

Securities litigation includes both federal class action suits (consolidated federal filings in many cases) and state securities class actions in Delaware and other jurisdictions. Modern media acquisition corp and similar SPACs have faced scrutiny where sponsor diligence fell short of what courts expected.

Legal framework: Securities Act, Exchange Act, and fiduciary duties

You don't need a law degree to understand the liability map. Here's how it works at each stage:

At the SPAC IPO stage, the sponsor files a Form S-1 for the shell company. Disclosures are limited because there's no operating business yet. Liability under the securities act applies to misstatements in the registration statement, but there's less to get wrong at this point.

At the de-SPAC stage, everything changes. The Form S-4 or proxy statement describes the target company's business, financial performance, projections, and deal terms. Under the 2024 rules, the target becomes a co-registrant, making both sponsor and target jointly liable under Securities Act Sections 11 and 12. Exchange Act Section 10(b) and Rule 10b-5 claims apply when there's scienter, meaning the sponsor or target knew or should have known statements were false. This is where the bulk of associated litigation risks sit.

Post-closing, the combined entity is a public company. Ongoing disclosure obligations apply. If pre-merger statements turn out to have been misleading, plaintiffs can bring claims referencing securities immediately prior to the business combination transaction and the private offering documents.

Key liability concepts:

State "Blue Sky" securities laws can add exposure, but most significant suits reference federal statutes and Delaware corporate law. The target IPO stage of the de-SPAC process is where your diligence either protects you or becomes evidence against you.

What "good" SPAC sponsor diligence looks like in practice

Treat this as a field manual. You have two to three weeks. Here's what to do.

1. Understand sponsor team history. Pull the backgrounds of every sponsor principal and board member. Look for prior SPACs, how those deals performed post-closing, any restatements, and any litigation history. Sponsors of SPACs include seasoned industry executives and financial experts, but credentials alone don't guarantee diligence quality. Talk to people who worked with them before.

2. Map incentives and cap table. Get the full picture of sponsor economics: founder shares (the promote), warrants, earn-outs, side letters, and any private investment arrangements. SPAC sponsors typically receive 20% of shares for minimal investment. After warrants and earn-outs, effective ownership can shift dramatically. Defensible valuations are typically 2 to 4 times the size of the SPAC's trust account. If the deal falls outside that range, ask why.

3. Interrogate target quality. SPAC sponsors focus on private companies with strong fundamentals and growth projections. Your job is to verify those claims independently. SPAC sponsors look for businesses with sustainable and predictable business models, but the question is whether the target actually has one.

Artifacts to collect:

4. Test projected value creation. Don't accept management's financial projections at face value. Run expert calls with former customers, suppliers, and commercial leaders at the target. Cross-reference revenue claims with channel checks. If the target is a private operating company in healthcare or fintech, talk to regulatory specialists about reimbursement or licensing risk.

5. Assess post-merger governance. Effective management teams are critical for SPAC target companies post-merger. Who is staying? Who is leaving? What board seats does the sponsor control? Does the combined entity have the infrastructure for achieving public company status, including audit readiness, internal controls, and compliance?

Deal timelines for closing a de-SPAC transaction include addressing redemption risks. SPACs must complete a merger within 18 to 24 months or liquidate. That deadline creates pressure. Your diligence process should account for it without being compromised by it.

Designing sponsor research to mitigate litigation risks

The connection between field research and risk reduction is direct. Every expert interview you run can test an assumption that would otherwise appear as an unsupported projection in an SEC filing. Here are the workstreams that matter most.

1. Product and technology validation. If the target claims proprietary technology or a differentiated product, talk to former engineers, product managers, and competitors. Can the technology do what the sponsor deck says it can? This is exactly what failed in the Momentus case, where technology claims proved false.

Sample questions: What is the actual state of the core product? How does it compare to alternatives? What are the known technical limitations?

2. Customer concentration and churn. How many customers generate what percentage of revenue? Are any of them building competitive alternatives? The MultiPlan case turned on exactly this issue. A single large customer developing in-house capabilities was a material risk that went undisclosed. The SPAC addressed it too late.

Sample questions: Which customers represent more than 10% of revenue? What's the renewal rate? Have any major accounts churned or signaled intent to leave?

3. Regulatory and reimbursement risk. For healthcare, fintech, and other regulated sectors, talk to former regulators, compliance officers, or advisory firms that specialize in the relevant regulatory body. Sponsors must ensure compliance with regulatory requirements in deal structures, and regulators don't care about your SPAC timeline.

4. Operational scalability. Targets must have scalable financial processes for public market readiness. Can the company handle quarterly reporting, SOX compliance, and the operational demands of public company status? Talk to former CFOs or controllers.

5. Management integrity and governance history. Run reference calls on the target's C-suite. Have they been involved in prior restatements, regulatory actions, or governance failures? A financial advisor involved in the deal may provide some of this context, but independent sources are better.

Document your findings so they support a "reasonable diligence process" narrative if disclosures are later challenged. Memos to file, board decks summarizing expert calls, explicit risk-factor edits linked to findings. This documentation is what makes the difference between a defensible position and a losing one.

Strong diligence does not eliminate exchange act or fiduciary duty risk. But it materially improves defenses and gives boards better grounds to decline or renegotiate weak deals.

Common SPAC sponsor research mistakes (and how to avoid them)

Here are the errors that show up again and again in litigation filings and post-mortem reviews.

Diligence failures don't just create legal exposure. They destroy returns. When the verification successful narrative falls apart post-closing, investors bear the cost.

How FieldSignal runs SPAC sponsor and de-SPAC diligence

FieldSignal structures SPAC-related projects around tight timelines, typically 7 to 14 days. We start by clarifying the thesis and key litigation exposures with your team, then scope specific questions tied to securities act, exchange act, and fiduciary duty concerns. The output is decision-ready transcripts and synthesis notes, not raw audio you have to wade through.

Typical buyers for this work include PE/VC associates evaluating a de-SPAC PIPE commitment, corporate M&A teams considering a strategic partnership with a de-SPAC'd company or a privately held company going public via SPAC, and sponsors themselves needing third-party checks to support board materials and strengthen their reasonable due diligence defense.

Here's the workflow:

  1. Clarify the thesis, key diligence questions, and the specific litigation exposures you're trying to mitigate.

  2. Build a target expert profile list: former employees, customers, suppliers, and regulatory specialists relevant to the target and the sponsor.

  3. Schedule interviews and panels within 5 to 10 business days. You control the questions. We handle sourcing, scheduling, and compliance screening.

  4. Produce transcripts and synthesis notes aligned to your diligence questions, formatted for board decks or counsel review.

Pricing is transparent. Pay-per-use, no annual retainer, no minimum commitment, and pass-through honoraria with no markup on expert fees. GLG, AlphaSights, Third Bridge, Guidepoint, Tegus, AlphaSense, Capvision, ProSapient, Coleman Research, Atheneum, Mosaic Research Management, and Inex One all operate with varying fee structures, but many require opaque retainers or annual minimums that price out smaller funds, boutique advisory firms, and mid-market corporate teams. FieldSignal doesn't.

Compliance, conflicts, and interview hygiene in SPAC research

SPAC-related expert calls demand strict compliance controls. There's MNPI risk when you're talking to people connected to a target near a de-SPAC business combination vote. There may be active SEC investigations. The stakes are high.

When accessing SEC filings and regulatory databases during SPAC research, you'll encounter standard online security checks. These are routine, but they remind you that the data you're pulling is being monitored and logged.

Key compliance safeguards FieldSignal maintains:

What your internal team should do:

Bad interview examples to avoid:

Well-run expert work is additive to counsel's advice, not a substitute. Structure it so findings are usable in disclosure drafting and board deliberations, and so you can point to the process as evidence of diligence if the deal is later challenged.

Practical sponsor research checklist before committing capital

Use this before signing a PIPE subscription, supporting a proxy, or recommending a de-SPAC deal internally. This sits alongside counsel's legal review. It doesn't replace it.

Sponsor team and track record:

Target company fundamentals:

Deal structure and dilution:

Litigation and regulatory risk review:

This checklist is meant to be printed as a one-to-two-page internal handout. Customize it for your deal. The point is to force specific answers to specific questions before you deploy capital.

Summary and next steps

De-SPAC transactions function like IPOs on liability. Sponsors sit at the center of litigation risks. Disciplined SPAC sponsor research is now a non-negotiable part of institutional capital deployment. SPACs raised approximately $113 billion in 2021. Shareholders filed 30 federal class action lawsuits involving SPACs by July 2021. The 2024 SEC rules only raised the bar further.

You mitigate SPAC litigation risks not by eliminating uncertainty but by building a documented, defensible diligence process that integrates expert interviews with financial, legal, and technical review. Every call you run, every memo you write, every risk factor you add to the proxy based on primary research strengthens your position.

What to do next:

See if FieldSignal fits your project → miles@fieldsignalhq.com

Join Our Network of 50,000+ Professionals

Our team is available to discuss your intelligence requirements Mon–Fri
Contact Us →
© 2026 Growth Insights Limited. All rights reserved.fieldsignalhq.com